ViferaXS is a clinical-stage biotechnology company developing peptide-based cancer immunotherapies.
ViferaXS has raised $13.7M in total funding. The most recent round was Series A. The last funding was announced in September 2026.
ViferaXS's investors include Huma, SPRIN-D.
ViferaXS is headquartered in Tübingen, Germany.
ViferaXS is a clinical-stage biotechnology company developing peptide-based cancer immunotherapies.
ViferaXS is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ViferaXS — Funding & Investors." VCBacked, September 23, 2026, https://www.vcbacked.co/company/viferaxs. Accessed October 2, 2026.
VCBacked. (2026). ViferaXS — Funding & Investors. Retrieved October 2, 2026, from https://www.vcbacked.co/company/viferaxs
{{cite web |title=ViferaXS — Funding & Investors |url=https://www.vcbacked.co/company/viferaxs |website=VCBacked |access-date=October 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated